Literature DB >> 19896187

The cytotoxic protease granzyme M is expressed by lymphocytes of both the innate and adaptive immune system.

Pieter J A de Koning1, Kiki Tesselaar, Niels Bovenschen, Selçuk Colak, Razi Quadir, Thomas J H Volman, J Alain Kummer.   

Abstract

The cytotoxic serine protease granzyme M (GrM) is one of the five human granzymes, which are mainly expressed by cytotoxic T lymphocytes and/or NK cells. Upon perforin-dependent entry into a target cell, GrM cleaves specific substrates resulting in the onset of a unique cell death mechanism. However, the role of GrM in pathophysiological conditions is not clear yet. Knowledge of the expression and regulation of GrM by lymphocyte populations is instrumental for a better understanding of the contribution of this unique granzyme in health and disease. Two previous studies demonstrated GrM protein expression by lymphocytes of the innate immune system, i.e., NK cells, NKT cells, and gammadelta T cells, whereas its expression by CD8(+) T cells remained controversial. In the present study, we have investigated the expression and regulation of GrM in lymphocyte subsets in more detail. Flow cytometry analysis with a novel specific antibody against human GrM confirmed high expression of this protease by NK cells, NKT cells, and gammadelta T cells. CD8(+) T cells also expressed GrM and comparing the naive to early effector-memory, to late effector-memory, to effector subset, this expression gradually increased during differentiation. In contrast, CD4(+) T cells hardly expressed GrM. Quantitative PCR analysis for GrM mRNA levels in the diverse lymphocyte sub-populations confirmed the FACS results. GrM protein expression by lymphocyte populations was not significantly affected by a panel of GrB-inducing cytokines, indicating that GrM expression is differentially regulated as compared to GrB. In conclusion, the human cytotoxic protease GrM is, besides by innate immune cells, also expressed by CD8(+) effector T cells, in particular by the differentiated effector CD27(-) CD45RO(-) subset. Our current findings support not only a role for GrM in the innate but also in the adaptive immune response. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19896187     DOI: 10.1016/j.molimm.2009.10.001

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  13 in total

Review 1.  γδ-T cells: an unpolished sword in human anti-infection immunity.

Authors:  Jian Zheng; Yinping Liu; Yu-Lung Lau; Wenwei Tu
Journal:  Cell Mol Immunol       Date:  2012-10-15       Impact factor: 11.530

2.  Serine protease inhibition attenuates rIL-12-induced GZMA activity and proinflammatory events by modulating the Th2 profile from estrogen-treated mice.

Authors:  Ebru Karpuzoglu; Chad W Schmiedt; Julian Pardo; Megan Hansen; Tai L Guo; Steven D Holladay; Robert M Gogal
Journal:  Endocrinology       Date:  2014-05-19       Impact factor: 4.736

Review 3.  Granzyme M: behind enemy lines.

Authors:  S A H de Poot; N Bovenschen
Journal:  Cell Death Differ       Date:  2014-01-10       Impact factor: 15.828

4.  Deep immune profiling by mass cytometry links human T and NK cell differentiation and cytotoxic molecule expression patterns.

Authors:  Bertram Bengsch; Takuya Ohtani; Ramin Sedaghat Herati; Niels Bovenschen; Kyong-Mi Chang; E John Wherry
Journal:  J Immunol Methods       Date:  2017-03-19       Impact factor: 2.303

5.  Granzyme M targets host cell hnRNP K that is essential for human cytomegalovirus replication.

Authors:  R van Domselaar; S A H de Poot; E B M Remmerswaal; K W Lai; I J M ten Berge; N Bovenschen
Journal:  Cell Death Differ       Date:  2012-10-26       Impact factor: 15.828

6.  Granzyme M targets topoisomerase II alpha to trigger cell cycle arrest and caspase-dependent apoptosis.

Authors:  S A H de Poot; K W Lai; L van der Wal; K Plasman; P Van Damme; A C Porter; K Gevaert; N Bovenschen
Journal:  Cell Death Differ       Date:  2013-11-01       Impact factor: 15.828

7.  Intracellular expression of granzymes A, B, K and M in blood lymphocyte subsets of critically ill patients with or without sepsis.

Authors:  M Isabel García-Laorden; Arie J Hoogendijk; Maryse A Wiewel; Lonneke A van Vught; Marcus J Schultz; Niels Bovenschen; Alex F de Vos; Tom van der Poll
Journal:  Clin Exp Immunol       Date:  2021-05-27       Impact factor: 4.330

8.  Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity.

Authors:  Martine J Hollestelle; Ka Wai Lai; Marcel van Deuren; Peter J Lenting; Philip G de Groot; Tom Sprong; Niels Bovenschen
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

9.  Intracellular serine protease inhibitor SERPINB4 inhibits granzyme M-induced cell death.

Authors:  Pieter J A de Koning; J Alain Kummer; Stefanie A H de Poot; Razi Quadir; Roel Broekhuizen; Anne F McGettrick; Wayne J Higgins; Bart Devreese; D Margaret Worrall; Niels Bovenschen
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

10.  NK cell intrinsic regulation of MIP-1α by granzyme M.

Authors:  N Baschuk; N Wang; S V Watt; H Halse; C House; P I Bird; R Strugnell; J A Trapani; M J Smyth; D M Andrews
Journal:  Cell Death Dis       Date:  2014-03-13       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.